Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000 Jan 20, 342(3), 145-153. [PMID]: 10639539.

Bosch J, Yusuf S, Pogue J, Sleight P, Lonn E, Rangoonwala B, Davies R, Ostergren J, Probstfield J; HOPE Investigators. Heart outcomes prevention evaluation. Use of ramipril in preventing stroke: double blind randomised trial. BMJ. 2002 Mar 23, 324(7339), 699-702. [PMID]: 11909785.

[No authors listed] Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet. 2000 Jan 22, 355(9200), 253-259. [PMID]: 10675071.

Lonn E, Shaikholeslami R, Yi Q, Bosch J, Sullivan B, Tanser P, Magi A, Yusuf S. Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction; A substudy of the Heart Outcomes Prevention Evaluation (HOPE) trial. J Am Coll Cardiol. 2004 Jun 16, 43(12), 2200-2206. [PMID]: 15193680.

Teo KK, Mitchell LB, Pogue J, Bosch J, Dagenais G, Yusuf S; HOPE Investigators. Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction. Circulation. 2004 Sep 14, 110(11), 1413-1417. [PMID]: 15353497.